Home Insights What’s new in the field of hematologic cell and gene therapy: Part II

What’s new in the field of hematologic cell and gene therapy: Part II

Julianne Dunphy, PhD, Global Director, Medical Strategy at Mind+Matter, part of EmerGENE, shares a series of standout findings presented at the 63rd American Society of Hematology (ASH) annual meeting and exposition in December 2021.

In today’s blog, Julianne explores the topic of patient gut microbiota and the implications this has on CAR-T treatment efficacy.

Patient gut microbiota may affect CAR-T cell treatment outcomes

Intriguing findings from a pair of studies, one clinical and one preclinical, have provided compelling evidence that a patient’s gut microbiome may have an impact on CAR-T treatment outcomes.

While the intestinal microbiota has been known to affect checkpoint-based immunotherapeutic treatment outcomes among others, the study by Melody Smith, MD et al. explored how the effect might extend to CD19-targeted CAR-T treatment in the clinical setting[i]. PIM antibiotics (piperacillin-tazobactam, imipenem-cilastatin, and meropenem) are known to modulate the gut microbiome. Interestingly, the study found that a group of ALL and NHL patients who had taken PIM antibiotics prior to treatment experienced worse outcomes, including inferior overall survival compared to patients that did not receive antibiotics. They also looked at the baseline microbial milieu in fecal samples from patients receiving CAR-T therapy compared to healthy controls. They found significantly lower microbial diversity in the CAR-T treatment-receiving group, a signal of gut microbiome perturbation already existing in these patients.

On the other hand, a preclinical study looking at the impact of the antibiotic vancomycin on CAR-T treatment outcomes showed an improvement in tumor responses in mice with cancer that had received the antibiotic treatment[ii]. Interestingly, this was true whether the mice had prior healthy donor fecal transplants or not, suggesting the result was unlikely unrelated to health of the baseline gut microbiome.

The questions this raises

These results show the importance of the bacterial milieu of the gut in CD19 CAR-T cell treatment efficacy (and safety, not discussed here) outcomes. This further highlights the important relationship between the gut microbiome and the immune systems. The data also underscore the complexity of these effects and raise numerous questions. Are there specific bacteria or classes therein associated with good outcomes or is it the sheer diversity that matters? What is the mechanism of the effect? And perhaps most importantly for the future, how can we utilize these findings in proactively managing the intestinal microbiome in patients receiving treatment? As is usually the case in hematology and oncology, further study and robust clinical trials are needed. Definitely a topic to watch.

Find out more

At EmerGENE, we are committed to exploring the latest advancements in C&GT to guide our customers in getting these life-changing treatments to patients. None of these studies could be done without the generous support and participation of the patients and caregivers and are the driving force behind what we do as well. For further insights, please visit here.


[i] Melody Smith, et al. 253 The Intestinal Microbiota Correlates with Response and Toxicity after CAR T Cell Therapy in Patients with B-Cell Malignancies. Abstract available at: https://ash.confex.com/ash/2021/webprogram/Paper153945.html

[ii] Marco Ruella, et al. 163 Gut Microbiota Tuning Promotes Tumor-Associated Antigen Cross Presentation and Enhances CAR T Antitumor Effects. Abstract available at: https://ash.confex.com/ash/2021/webprogram/Paper151093.html


Other similar insights

Ashfield launches Cell and Gene Therapy Commercialization Network, EmerGENE

Ashfield announces the launch of EmerGENE, a global end-to-end cell and gene therapy network supporting small and midsize biotechs.

Read more

Assessing the commercial opportunity for a new CAR-T therapy

Read how we assessed the commercial opportunity for a new CAR-T therapy.

Read more

What’s in store for cell and gene therapy?

Cell therapies have come a long way since the first successful stem cell transplant in 1972.

Read more

3 trends shaping commercialization in the cell and gene therapy sector

Disharee Nath, PhD, Associate Medical Director at Mind+Matter, attended the two-day Cell & Gene Therapy USA (Sep ’21) conference organized by Reuters.

Read more

Improving patient experience in Cell and Gene Therapies through a data-centric approach

Cell and gene therapies (C&GTs) continue to expand with 3,366 currently in preclinical and clinical development.

Read more

SITC 2021 round-up: does the new generation of Cell and Gene Therapies give us hope for tackling solid tumors?

The SITC Conference 2021 presented such an opportunity, offering up plenty of interesting insight for us to explore.

Read more

What’s new in the field of hematologic cell and gene therapy: Part I

The largest conference of its kind in the world, ASH is attended by more than 25,000 industry professionals from across the globe.

Read more

What’s new in the field of hematologic cell and gene therapy: Part III

Julianne Dunphy shares a series of standout findings presented at the 63rd American Society of Hematology (ASH) annual meeting and exposition.

Read more